Preliminary Results of the Effects of Localized High-Dose Radiotherapy Combined with Total Body Low-Dose Irradiation on Tumor Growth and Stimulating the Immune System in Tumor-Bearing Mice.
IFN-γ
Immune System
Radiotherapy
Whole-Body Irradiation
Journal
Journal of biomedical physics & engineering
ISSN: 2251-7200
Titre abrégé: J Biomed Phys Eng
Pays: Iran
ID NLM: 101589641
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
12
09
2020
accepted:
03
01
2021
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
The immune system plays an extensive role in eliminating tumor cells. On the other hand, low-dose irradiation stimulates the immune system. The present study aimed to investigate the therapeutic outcomes of localized high-dose radiotherapy (LH) alone and combined with total body low-dose irradiation (TB). In this experimental study, B16F0 tumor cells were injected into the right flank of C57JL/6 mice. The mice were treated with LH alone (13 Gy X-rays to the tumor surface) (LH group) or combined with TB (85 mGy X-rays at the skin) (TB+LH group). Then the tumor volume, the mice's lifespan, the number of lymphocytes extracted from the spleen, and interferon gamma (IFN-γ) production were measured. Reduced number of lymphocytes, compared to non-irradiated mice (control group), was observed in LH and TB+LH groups. However, the identical number of cultured lymphocytes produced a higher level of IFN-γ in irradiated groups. Comparing the irradiated groups, the number of lymphocytes and their IFN-γ production, tumor growth control, and the mice's lifespan were statistically higher in TB+LH group. Observing a higher level of IFN-γ in TB+LH group compared to LH group indicates that low-dose radiation enhanced the stimulating effects of high-dose radiation on the immune system. It caused the mice in TB+LH group to have a more prolonged lifespan and a lower tumor growth rate. Therefore, it is worth our attention for future studies to investigate whether total body low-dose irradiation can be utilized before radiotherapy to enhance its efficiency.
Sections du résumé
Background
UNASSIGNED
The immune system plays an extensive role in eliminating tumor cells. On the other hand, low-dose irradiation stimulates the immune system.
Objective
UNASSIGNED
The present study aimed to investigate the therapeutic outcomes of localized high-dose radiotherapy (LH) alone and combined with total body low-dose irradiation (TB).
Material and Methods
UNASSIGNED
In this experimental study, B16F0 tumor cells were injected into the right flank of C57JL/6 mice. The mice were treated with LH alone (13 Gy X-rays to the tumor surface) (LH group) or combined with TB (85 mGy X-rays at the skin) (TB+LH group). Then the tumor volume, the mice's lifespan, the number of lymphocytes extracted from the spleen, and interferon gamma (IFN-γ) production were measured.
Results
UNASSIGNED
Reduced number of lymphocytes, compared to non-irradiated mice (control group), was observed in LH and TB+LH groups. However, the identical number of cultured lymphocytes produced a higher level of IFN-γ in irradiated groups. Comparing the irradiated groups, the number of lymphocytes and their IFN-γ production, tumor growth control, and the mice's lifespan were statistically higher in TB+LH group.
Conclusion
UNASSIGNED
Observing a higher level of IFN-γ in TB+LH group compared to LH group indicates that low-dose radiation enhanced the stimulating effects of high-dose radiation on the immune system. It caused the mice in TB+LH group to have a more prolonged lifespan and a lower tumor growth rate. Therefore, it is worth our attention for future studies to investigate whether total body low-dose irradiation can be utilized before radiotherapy to enhance its efficiency.
Identifiants
pubmed: 37609506
doi: 10.31661/jbpe.v0i0.2009-1179
pii: JBPE-13-4
pmc: PMC10440410
doi:
Types de publication
Journal Article
Langues
eng
Pagination
323-332Informations de copyright
Copyright: © Journal of Biomedical Physics and Engineering.
Déclaration de conflit d'intérêts
None
Références
Mutat Res Rev Mutat Res. 2014 Jul - Sep;761:6-14
pubmed: 24566131
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Radiat Res. 2004 Mar;161(3):335-40
pubmed: 14982480
Sci Rep. 2017 Feb 27;7:43361
pubmed: 28240233
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1306-10
pubmed: 22208977
Cancer Lett. 2015 Nov 28;368(2):246-51
pubmed: 25892550
Cancer Lett. 2015 Jan 1;356(1):5-16
pubmed: 24045041
Br J Radiol. 2005 Jan;78(925):3-7
pubmed: 15673519
Radiat Res. 2008 Oct;170(4):477-87
pubmed: 19024655
Hum Exp Toxicol. 2015 Mar;34(3):272-83
pubmed: 24925363
Clin Dev Immunol. 2011;2011:439752
pubmed: 22162711
Int J Mol Sci. 2014 Jan 10;15(1):927-43
pubmed: 24434638
Nat Rev Cancer. 2004 Sep;4(9):737-47
pubmed: 15343280
Health Phys. 2016 Mar;110(3):293-5
pubmed: 26808887
Cancer Immunol Immunother. 2014 Jan;63(1):29-36
pubmed: 24052136
Crit Rev Oncol Hematol. 2013 Mar;85(3):278-87
pubmed: 23036459
PLoS One. 2014 Mar 31;9(3):e92572
pubmed: 24686897
Cancer Biother Radiopharm. 2014 Dec;29(10):428-34
pubmed: 25402754
Exp Ther Med. 2017 Oct;14(4):3868-3873
pubmed: 29042994
Int J Radiat Biol. 2007 Jun;83(6):395-408
pubmed: 17487679